2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
74
Hodgkin Disease
56
Lymphoma
22
Sarcoma
13
Neoplasm Metastasis
11
Leiomyosarcoma
8
Uveal Melanoma
7
Neoplasms
7
Skin Neoplasms
6
Neuroblastoma
4
Sarcoma, Synovial
3
Recurrence
3
Solitary Fibrous Tumors
2
Sarcoma, Alveolar Soft Part
2
Hematologic Diseases
2
HIV Infections
2
Thyroid Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Melanoma, Cutaneous Malignant
1
Melanoma Neoplasms
1
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
9
Bevacizumab
8
toripalimab
7
senaparib
7
Fluorodeoxyglucose F18
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Fluorouracil
6
Gemcitabine
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
spartalizumab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Midazolam
3
Itraconazole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
Dacarbazine
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled